A new study led by UCL researchers is a large-scale comparison of direct oral anticoagulants (blood thinners), commonly prescribed for irregular heartbeats.
In the article published in Annals of Internal MedicineThe researchers reported that one of the two most popular direct oral anticoagulants (DOACs), apixaban, offered the lowest risk of gastrointestinal bleeding, with similar performance. stroke prevention and other side effects.
DOAC is used to prevent stroke in people with atrial fibrillation—Slow or irregular heartbeat—A condition that affects more than 33 million people worldwide. Recently, they have become more popular than warfarin, the previous standard treatment, because they do not require as much monitoring (especially valuable during the COVID-19 pandemic) and have less risk of side effects. than.
For the new study, researchers compared the effectiveness and risk of side effects of the four most common types of DOACs. They looked at data from more than 500,000 new DOAC users in the UK, France, Germany, and the US, including 281,320 apixaban users, 61,008 dabigatran users, 12,722 edoxaban users, and 172,176 rivaroxaban users.
They found that all four drugs were comparable in outcomes for ischemic strokebrain bleeding and all-cause mortality, while they identified a difference in risk of gastrointestinal bleeding, this is one of the most common and DOAC-related adverse events.
The study found that apixaban had a lower risk of gastrointestinal bleeding, with a 19-28% lower risk when compared directly with each of the other three DOACs.
The researchers found that their findings held true when they only looked at data from people over the age of 80 and those with chronic kidney diseasetwo groups are rarely presented in clinical trials.
Co-lead author, Dr. Wallis Lau (UCL School of Pharmacy) said, “Direct oral anticoagulants have been prescribed with increasing frequency worldwide in recent years, but the evidence compares comparing them directly is limited.Our results indicate that apixaban may like more than the other blood thinners because of lower rates of gastrointestinal bleeding and similar rates of stroke, a finding that we hope will be supported by randomized controlled trials.
“As with all drugs, the potential risks and benefits can vary from person to person, so a full review of outcomes and side effects will still be necessary for each patient.”
Comparison of efficacy and safety between Apixaban, Dabigatran, Edoxaban and Rivaroxaban among patients with atrial fibrillation, Annals of Internal Medicine (In 2022). DOI: 10.7326 / M22-0511
University of London
Quote: Researchers identifying the best blood thinners to minimize bleeding risk (2022, October 31) retrieved November 1, 2022 from https://medicalxpress.com/news/2022- 10-blood-thinner-minimizing.html
This document is the subject for the collection of authors. Other than any fair dealing for personal study or research purposes, no part may be reproduced without written permission. The content provided is for informational purposes only.